MedTrace Logo

Allogeneic CART-19 for Elderly Relapsed/Refractory CD19+ ALL

NCT02799550 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2019-02-25

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and efficiency of allogeneic cluster of differentiation 19 (CD19)-directed chimeric antigen receptor modified T cells (CART-19) infusions in patients with relapsed / refractory B-cell acute lymphoblastic leukemia (B-ALL)

Conditions

Interventions

BIOLOGICAL

allogeneic CART-19

allogeneic CD19-directed chimeric antigen receptor-modified T cells (CART-19)

Sponsors & Collaborators

  • Chinese PLA General Hospital

    collaborator OTHER

  • The Affiliated Hospital of the Chinese Academy of Military Medical Sciences

    lead OTHER

Principal Investigators

  • Huisheng Ai, MD · Affiliated Hospital of Academy of Military Medical Sciences

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-31
Primary Completion
2019-05-31
Completion
2020-05-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02799550 on ClinicalTrials.gov